Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

6.4K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.4K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

873
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
873
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

532
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
532
Accessory Structures of the Skin: Hair Growth and Types01:20

Accessory Structures of the Skin: Hair Growth and Types

2.8K
Hair growth begins with the production of keratinocytes by the basal cells of the hair bulb. As new cells are deposited at the hair bulb, the hair shaft is pushed through the follicle toward the surface. Keratinization is completed as the cells are pushed to the skin surface to form the shaft of hair that is externally visible. The external hair is completely dead and composed entirely of keratin. Hair can be cut or shaven without damaging the hair structure because the cut is superficial. Most...
2.8K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

274
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
274
Angina IV: Management01:26

Angina IV: Management

368
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
368

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association Between Omalizumab and Alopecia Areata Risk: A Retrospective Cohort Study.

International journal of dermatology·2026
Same author

Cutaneous inflammatory biomarkers in rosacea and their association with disease severity.

Clinical and experimental dermatology·2026
Same author

Multidimensional burden of scarring alopecia in women: findings from the CAPAIR study.

International journal of women's dermatology·2026
Same author

Assessment and Clinical Management of Patients With Atopic Dermatitis Undergoing Patch Testing: Recommendations From an International Electronic Delphi Consensus.

Dermatitis : contact, atopic, occupational, drug·2026
Same author

Prevalence and incidence of primary lymphocytic cicatricial alopecias in the United States from 2019 to 2024.

JAAD international·2026
Same author

Association Between Type I Interferonopathies and the Development of Cutaneous Sarcoidosis, Morphea, Lichen Planus and Granuloma Annulare: A Retrospective Cohort Study.

Experimental dermatology·2026

Related Experiment Video

Updated: Mar 6, 2026

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
06:41

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Published on: March 9, 2015

9.5K

Exploring novel management options for alopecia areata.

Libbi Green1, Emma Guttman2, Mark Lebwohl2

  • 1Clinical Operations, Capital Rx, New York, NY.

The American Journal of Managed Care
|March 4, 2026
PubMed
Summary

Alopecia areata (AA) is an autoimmune disease causing hair loss. JAK inhibitors like baricitinib, ritlecitinib, and deuruxolitinib show promise in treating severe AA by targeting the JAK-STAT pathway.

More Related Videos

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.7K
Stimulation of Stem Cell Niches and Tissue Regeneration in Mouse Skin by Switchable Protoporphyrin IX-Dependent Photogeneration of Reactive Oxygen Species In Situ
10:05

Stimulation of Stem Cell Niches and Tissue Regeneration in Mouse Skin by Switchable Protoporphyrin IX-Dependent Photogeneration of Reactive Oxygen Species In Situ

Published on: May 8, 2020

2.3K

Related Experiment Videos

Last Updated: Mar 6, 2026

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
06:41

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Published on: March 9, 2015

9.5K
Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.7K
Stimulation of Stem Cell Niches and Tissue Regeneration in Mouse Skin by Switchable Protoporphyrin IX-Dependent Photogeneration of Reactive Oxygen Species In Situ
10:05

Stimulation of Stem Cell Niches and Tissue Regeneration in Mouse Skin by Switchable Protoporphyrin IX-Dependent Photogeneration of Reactive Oxygen Species In Situ

Published on: May 8, 2020

2.3K

Area of Science:

  • Immunodermatology
  • Autoimmune diseases
  • Hair follicle biology

Background:

  • Alopecia areata (AA) is a chronic autoimmune condition impacting hair follicles.
  • AA presents significant psychosocial and economic burdens.
  • Current AA treatments face challenges due to disease heterogeneity and recurrence.

Purpose of the Study:

  • To review current management strategies for alopecia areata.
  • To highlight the role of the JAK-STAT pathway in AA pathogenesis and treatment.
  • To discuss the clinical and economic implications of recognizing AA as a complex immune-mediated disease.

Main Methods:

  • Review of current literature on alopecia areata.
  • Analysis of the role of the JAK-STAT pathway in AA.
  • Examination of FDA-approved JAK inhibitors for severe AA.

Main Results:

  • Three JAK inhibitors (baricitinib, ritlecitinib, deuruxolitinib) are FDA-approved for severe AA.
  • Phase 3 trials demonstrate the safety and efficacy of these JAK inhibitors.
  • The JAK-STAT pathway is a key therapeutic target for AA.

Conclusions:

  • Recognizing AA as a complex immune condition is crucial for patient outcomes.
  • Aligning managed care with clinical perspective can improve access to therapy.
  • Timely access to targeted therapies may reduce long-term disease consequences.